InternationalAvailable in English
Exclusive: OpenAI has acquired Orchestra Bio
Editorial
Cross Lines editing
Source
Axios
Axios
A
Axios
Original Source
OpenAI, the maker of ChatGPT, has acquired Orchestra Bio, a startup developing AI agents that help pharmaceutical companies manage drug development. The deal reflects a broader race among leading AI companies to expand into science and life sciences.
Exclusive: OpenAI has acquired Orchestra Bio
*
* Newsletters
*
* Axios Pro
* Axios Live
* The Axios Show
Axios
Axios
6 hours ago - Business
Exclusive: OpenAI acquires biotech startup as AI race moves into drug development
* Madison Mills
*
*
*
Add Axios on Google
Add Axios as your preferred source to
see more of our stories on Google.
Add Axios on Google
!Illustration of a pill at the center of a quantum symbol.
*Illustration: Maura Losch/Axios*
OpenAI has acquired Orchestra Bio, a startup building AI agents to help pharmaceutical companies manage drug development, the ChatGPT maker shared exclusively with Axios.
**Why it matters:** Rival AI giants OpenAI and Anthropic are both pushing into science as they look to expand beyond their core competencies in coding and cybersecurity.
**State of play:** OpenAI will integrate Orchestra's team and technology into Rosalind, its suite of AI models and tools designed for life sciences researchers, the company said.
* Orchestra's platform allows scientists to delegate tasks like monitoring studies, tracking drug development timelines and identifying potential delays to AI agents.
* Both companies aim to deploy agents that can connect scientific findings with the decisions and next steps required to advance potential treatments.
* Financial terms of the acquisition were not disclosed.
**Between the lines:** AI companies don't just want to increase productivity, they want to say they are responsible for, say, curing cancer, solving math, and fundamentally changing every critical industry in the world.
* Those ambitions have fueled acquisitions from rival AI labs.
* Anthropic acquired AI biotech startup Coefficient Bio for roughly $400 million in April, according to The Information.
**Zoom in:** OpenAI introduced its specialized GPT-Rosalind model in April to help researchers tackle complex problems in biology, chemistry and drug discovery.
* OpenAI has also partnered with pharmaceutical giants including Novo Nordisk and Moderna to bring AI into research and development workflows.
* OpenAI says developing a new medicine typically takes 10 to 15 years, a timeline it hopes AI can shorten.
**Zoom out** Anthropic has been making its own aggressive push into life sciences.
* In June, Anthropic launched Claude Science, an AI-powered research platform that connects scientific databases, analysis tools and specialized agents.
* In September, the company announced a new biological research lab and said Claude had helped discover a previously unknown enzyme system with similarities to CRISPR, though some scientists said these finders were overblown, per Bloomberg.
**The bottom line:** The AI race is shifting from building the best models to applying that intelligence across industries.
* Several AI investors told Axios a key question as AI companies go public is how far they can expand into new markets.
*
*
*
Add Axios on Google
What to read next
*
*
*
*
*
*
Smarter, faster on what matters.
Explore Axios Newsletters
* About Axios
* Advertise with us
* Careers
* Contact us
* Newsletters
* Axios Live
* Axios HQ
* Privacy policy
* Terms of use
*
Axios Homepage
Axios Media Inc., 2026
*
* Newsletters
*
* Axios Pro
* Axios Live
* The Axios Show
Axios
Axios
6 hours ago - Business
Exclusive: OpenAI acquires biotech startup as AI race moves into drug development
* Madison Mills
*
*
*
Add Axios on Google
Add Axios as your preferred source to
see more of our stories on Google.
Add Axios on Google
!Illustration of a pill at the center of a quantum symbol.
*Illustration: Maura Losch/Axios*
OpenAI has acquired Orchestra Bio, a startup building AI agents to help pharmaceutical companies manage drug development, the ChatGPT maker shared exclusively with Axios.
**Why it matters:** Rival AI giants OpenAI and Anthropic are both pushing into science as they look to expand beyond their core competencies in coding and cybersecurity.
**State of play:** OpenAI will integrate Orchestra's team and technology into Rosalind, its suite of AI models and tools designed for life sciences researchers, the company said.
* Orchestra's platform allows scientists to delegate tasks like monitoring studies, tracking drug development timelines and identifying potential delays to AI agents.
* Both companies aim to deploy agents that can connect scientific findings with the decisions and next steps required to advance potential treatments.
* Financial terms of the acquisition were not disclosed.
**Between the lines:** AI companies don't just want to increase productivity, they want to say they are responsible for, say, curing cancer, solving math, and fundamentally changing every critical industry in the world.
* Those ambitions have fueled acquisitions from rival AI labs.
* Anthropic acquired AI biotech startup Coefficient Bio for roughly $400 million in April, according to The Information.
**Zoom in:** OpenAI introduced its specialized GPT-Rosalind model in April to help researchers tackle complex problems in biology, chemistry and drug discovery.
* OpenAI has also partnered with pharmaceutical giants including Novo Nordisk and Moderna to bring AI into research and development workflows.
* OpenAI says developing a new medicine typically takes 10 to 15 years, a timeline it hopes AI can shorten.
**Zoom out** Anthropic has been making its own aggressive push into life sciences.
* In June, Anthropic launched Claude Science, an AI-powered research platform that connects scientific databases, analysis tools and specialized agents.
* In September, the company announced a new biological research lab and said Claude had helped discover a previously unknown enzyme system with similarities to CRISPR, though some scientists said these finders were overblown, per Bloomberg.
**The bottom line:** The AI race is shifting from building the best models to applying that intelligence across industries.
* Several AI investors told Axios a key question as AI companies go public is how far they can expand into new markets.
*
*
*
Add Axios on Google
What to read next
*
*
*
*
*
*
Smarter, faster on what matters.
Explore Axios Newsletters
* About Axios
* Advertise with us
* Careers
* Contact us
* Newsletters
* Axios Live
* Axios HQ
* Privacy policy
* Terms of use
*
Axios Homepage
Axios Media Inc., 2026
Share Article
Tags:#أوبن إيه آي#أوركسترا بيو#الذكاء الاصطناعي#تطوير الأدوية#أنثروبيك#التكنولوجيا الحيوية
Source: Axios
For Context
Related reads from the same topic or latest developments
